Bryan Johnson Longevity Protocol: What It Would Cost a Non-Celebrity

What Exactly Is Bryan Johnson's Blueprint Protocol?

Blueprint is Johnson's self-funded, physician-supervised program aimed at reducing biological age as measured across multiple organ systems. Johnson has described it publicly through his podcast appearances, his own website (blueprint.bryanjohnson.com), and various media interviews as a data-driven system for making decisions about his body rather than relying on subjective judgment or willpower.

The protocol is not a single pill or product. It combines diet, sleep, exercise, prescription medications, and frequent diagnostic testing. Blueprint's own published documentation lists a large number of supplement servings daily, including items such as vitamin D3, omega-3 fatty acids, N-acetylcysteine (NAC), vitamin C, and lutein/zeaxanthin. On the prescription side, Johnson has publicly disclosed taking metformin, rapamycin, acarbose, low-dose lithium orotate, topical testosterone, and at various points a GLP-1 receptor agonist.

The Philosophy Behind the Protocol

Johnson's stated rationale is that human willpower is an unreliable controller of health behavior, so he wants a data-driven system making decisions instead. Each intervention is chosen by his clinical team based on his own biomarker response rather than population averages alone. That is a defensible clinical principle in general, even though the scale of monitoring involved is far beyond what most physicians can offer a typical patient.

What the Protocol Is Not

Blueprint is not a peer-reviewed clinical protocol tested against a control group. Johnson is a sample size of one, and his personal results cannot be generalized without larger controlled trials. Public commentary from physicians in the longevity field, including members of Johnson's own clinical team, has acknowledged that the strength of evidence varies widely across the individual interventions in the stack, from well-supported (metformin's glycemic effects) to speculative (some peptide use). Readers should treat any single-person case as a hypothesis-generating anecdote, not proof that a given intervention works.

The Prescription Drug Stack: Science and Cost

The prescription component is the most medically significant part of Blueprint. Nearly all of these drugs are being used off-label for longevity purposes rather than for the condition they were originally approved to treat. The FDA describes off-label use as prescribing an approved drug for a use, population, or dose not listed on its label, which is legal but places the responsibility for weighing risk and benefit on the prescribing physician. (FDA: Understanding Unapproved Use of Approved Drugs)

Metformin

Metformin is the most evidence-supported drug in Johnson's stack for longevity purposes, though even here the human trial evidence is still developing. The Targeting Aging with Metformin (TAME) trial, an NIH-supported randomized controlled trial planned to enroll around 3,000 participants aged 65 to 79, is testing whether metformin delays the composite incidence of age-related diseases. Results are expected later in the decade. [1]

Metformin activates AMPK, modestly inhibits mTORC1, and reduces hepatic glucose output. A UK-based observational analysis of people with type 2 diabetes found that those taking metformin lived as long as, or in some comparisons longer than, matched non-diabetic controls not taking the drug, though the authors themselves note that residual confounding limits how this should be interpreted. [2] This is associational evidence, not proof that metformin extends lifespan in people without diabetes.

Cost for non-celebrities: Generic metformin ER 500 mg typically costs roughly $4 to $12 per month at most U.S. pharmacies with a discount card. Off-label prescribing for longevity is legal but requires a willing physician, since there is no diagnosis code for "longevity" prevention.

Rapamycin (Sirolimus)

Rapamycin is an mTOR inhibitor approved as an immunosuppressant for organ transplant recipients. In the Interventions Testing Program (ITP), a rigorous NIA-funded multi-site program that tests compounds in genetically heterogeneous mice under standardized conditions, rapamycin has been the most consistently life-extending compound tested, extending median lifespan across multiple cohorts and doses even when started relatively late in life. [3]

Johnson has said he takes rapamycin on a weekly pulse schedule rather than daily; his exact dose has not been independently confirmed. Weekly dosing is used by longevity physicians to try to preserve mTOR-inhibition benefits while reducing the immunosuppression risk associated with continuous transplant-level dosing, but this dosing strategy has not been validated in a large controlled human longevity trial.

Risks: Mouth sores, elevated lipids, glucose intolerance, and immune suppression are documented risks in transplant patients on continuous dosing, and remain a concern at lower pulse doses. Rapamycin is not FDA-approved for longevity or anti-aging use in healthy adults, and anyone considering it should do so only with physician oversight and lab monitoring.

Cost for non-celebrities: Generic sirolimus tablets typically run roughly $150 to $400 per month for pulse dosing, depending on the pharmacy and manufacturer discounts.

Acarbose

Acarbose is an alpha-glucosidase inhibitor that blunts post-meal glucose spikes. It is FDA-approved for type 2 diabetes and is used off-label here. In the ITP, acarbose extended median lifespan in mice, with a larger effect seen in males than in females at the doses tested. [4]

Cost for non-celebrities: Generic acarbose typically costs roughly $30 to $80 per month at standard dosing.

Low-Dose Lithium

Johnson has stated he takes low-dose lithium orotate (reportedly around 1 mg per day), which is distinct from the lithium carbonate used at much higher doses (600 to 1,800 mg per day) to treat bipolar disorder. A Danish nationwide study found an association between higher lithium concentrations in municipal drinking water and lower dementia incidence. [5] This is an ecological, population-level association based on water supply, not a clinical trial of individual lithium supplementation, and it does not establish that taking a low-dose lithium orotate supplement prevents dementia in an individual. Anyone considering lithium in any form should have kidney and thyroid function monitored, since lithium affects both organs even at low doses.

Cost for non-celebrities: Over-the-counter lithium orotate supplements typically cost roughly $15 to $25 per month.

Testosterone (Topical)

Johnson uses topical testosterone to maintain levels toward the upper end of the normal physiological range. Testosterone decline with age is well documented, and AUA/Endocrine Society guidance recognizes quality-of-life and body-composition benefits of testosterone therapy in men with confirmed hypogonadism (biochemically low testosterone with symptoms). [6] These guidelines and the underlying trial evidence are about treating men with confirmed low testosterone, not about raising already-normal testosterone toward the top of the reference range in an asymptomatic person. Cardiovascular safety data for testosterone therapy in men with existing risk factors are mixed and continue to be studied.

Cost for non-celebrities: Compounded topical testosterone typically runs roughly $40 to $120 per month. FDA-approved branded products are substantially more expensive without insurance coverage, and insurance generally requires a documented hypogonadism diagnosis.

GLP-1 Receptor Agonist

Johnson has publicly discussed using a GLP-1 agonist such as semaglutide as part of metabolic optimization. In the STEP-1 trial of semaglutide 2.4 mg (Wegovy) in adults with obesity or overweight, participants lost substantially more weight over 68 weeks than those on placebo, with a difference of roughly 12 percentage points. [7] The later SELECT trial found that semaglutide 2.4 mg reduced major adverse cardiovascular events in overweight or obese adults with established cardiovascular disease but without diabetes. [8] Both trials enrolled people with overweight, obesity, or established cardiovascular risk; using a GLP-1 agonist purely for longevity in someone who is already at a healthy weight and metabolically well is an extrapolation beyond the studied population, and this use has not been shown to extend lifespan.

Cost for non-celebrities: Branded Wegovy typically costs roughly $1,300 to $1,500 per month without insurance. Compounded semaglutide through a telehealth provider can run roughly $200 to $500 per month, though compounded GLP-1 products are not FDA-approved and their manufacturing is less tightly regulated than branded products. Ozempic, approved for type 2 diabetes, is often covered by insurance only when there is a qualifying diagnosis.

The Supplement Stack: Which Parts Have Real Evidence?

Johnson's publicly documented supplements fall into three rough tiers based on the strength of human clinical evidence behind each one.

Tier 1: Supported by human trial data

• Omega-3 (high-dose EPA/DHA): In the REDUCE-IT trial of the prescription EPA formulation icosapent ethyl in patients with elevated triglycerides already on statin therapy, treatment reduced major cardiovascular events compared with placebo. [9] This trial studied people with elevated triglycerides and existing cardiovascular risk; the cardiovascular benefit has not been established in people without those risk factors.
• Vitamin D3: The VITAL trial found that vitamin D3 supplementation did not significantly reduce major cardiovascular events or overall cancer incidence in a general older-adult population, though it found a reduction in cancer mortality in secondary analysis. [10] Vitamin D3 correcting a documented deficiency is a different clinical question than supplementing someone who is already replete, and VITAL did not test biological-age outcomes.
• Magnesium L-threonate: A randomized, placebo-controlled trial of a magnesium L-threonate compound (MMFS-01) in older adults with cognitive complaints found improvements in measures of cognitive function. [11] This was a single trial in people with existing cognitive complaints, not in cognitively healthy adults, and the finding needs replication before it can be generalized.

Tier 2: Animal or mechanistic data only, reasonable clinical hypothesis

• NMN/NR (NAD+ precursors): These restore NAD+ levels that decline with age in rodent models. Small human pharmacokinetic studies confirm that oral NMN or NR raises blood NAD+ levels, but no completed large-scale human trial has shown a longevity or healthspan benefit.
• Spermidine: An autophagy-inducing compound with life-extension data in yeast, worms, flies, and mice. Human evidence is limited to small observational work suggesting a possible cognitive association, not a controlled trial of supplementation.
• Fisetin: A senolytic (senescent-cell-clearing) compound with mouse data. Human trials are underway, but efficacy in humans has not yet been established.

Tier 3: Speculative or highly individualized

• Peptides Johnson has discussed at various points, including BPC-157 and thymosin alpha-1, fall here. These lack strong human trial evidence for longevity endpoints, some are not FDA-approved for any indication, and their use carries regulatory and safety uncertainty. Blueprint's public documentation has changed over time, so any specific peptide use should be verified against current disclosures rather than assumed.

Diet and Lifestyle: The Low-Cost Components

Some of Blueprint's most defensible interventions cost little or nothing.

Caloric Structure

Johnson eats a vegan diet within a compressed eating window, generally finishing his last meal before 11 a.m. This resembles time-restricted eating protocols studied in obesity research. A randomized trial of 16:8 time-restricted eating (the TREAT trial) found that it did not produce significantly greater weight loss than a standard eating pattern with similar calorie intake over 12 weeks. [12] Time-restricted eating may help some people manage intake by limiting the window in which they eat, but the trial evidence does not show it outperforms simple caloric awareness. Johnson's diet is also fully vegan, high in fiber, and built around whole foods such as broccoli, cauliflower, hemp seeds, and extra-virgin olive oil, which is a separate and more established set of dietary choices from the timing question.

Sleep Architecture

Johnson targets around 8 hours of sleep with consistent timing, tracked with an EEG headband. Genetic epidemiological research has found that shorter genetically predicted sleep duration is associated with a higher risk of myocardial infarction. [13] This kind of study helps establish that the sleep-cardiovascular link is unlikely to be pure reverse causation, but it does not define an exact optimal sleep duration for every individual, and normal sleep needs vary by person.

Cost: Consumer EEG sleep headbands cost roughly $200 to $500 once. Standard sleep hygiene practices, consistent bed and wake times, a dark and cool room, and limiting late caffeine, cost nothing.

Exercise

Johnson performs roughly an hour of daily structured exercise combining resistance training and lower-intensity cardio, and tracks VO2 max as a primary metric. A large cohort study of adults undergoing exercise treadmill testing found that each 1-MET increase in measured cardiorespiratory fitness was associated with a meaningfully lower risk of all-cause mortality, with the largest relative benefit at the low end of the fitness spectrum. [14] This is one of the most consistently reproduced findings in preventive medicine and applies broadly across ages and starting fitness levels.

Cost: Free using body weight and running. A gym membership adds roughly $25 to $80 per month.

Diagnostics and Monitoring: The Hidden Cost Driver

Johnson's protocol includes continuous glucose monitoring, frequent full-body MRI and DEXA scans, VO2 max testing, and a large panel of blood biomarkers drawn multiple times per year. This is where costs escalate the most for anyone trying to replicate the program, and it is also the area with the least individualized evidence: routine whole-body imaging in people without symptoms or known risk factors is not a standard, guideline-recommended screening practice, and it carries a real risk of incidental findings that lead to further testing without a clear benefit.

A Realistic Monitoring Budget for Non-Celebrities

• CGM (Dexcom G7 or Libre 3): roughly $75 to $150 per month without insurance
• Annual DEXA scan: roughly $50 to $200 depending on the facility
• Comprehensive metabolic panel and CBC, drawn quarterly: roughly $30 to $80 per draw at direct-pay labs
• Full lipid panel with ApoB and Lp(a), annually: roughly $40 to $100 direct-pay
• Testosterone, IGF-1, and DHEA-S panel: roughly $60 to $150 direct-pay
• Annual VO2 max test: roughly $150 to $300 at a sports medicine clinic
• Whole-body MRI: roughly $2,500, and most people who choose this do it once rather than quarterly, and should discuss the decision with a physician first given the incidental-finding risk

A reasonable annual monitoring budget for a motivated non-celebrity comes to roughly $3,000 to $5,000 per year. Johnson's own monitoring spend has not been broken out publicly with enough detail to state a reliable dollar figure for that category alone.

What a Non-Celebrity Should Actually Consider

Not every element of Blueprint carries the same evidence weight, safety profile, or expected return per dollar spent.

The Higher-Value Core (Accessible to Most People)

The interventions with the best evidence-to-cost ratio for a generally healthy adult trying to support healthy aging are: metformin if a physician agrees it is appropriate, a GLP-1 agonist if metabolic risk factors such as obesity or elevated cardiovascular risk are actually present, omega-3 at a therapeutic dose if triglycerides are elevated, vitamin D3 if a blood test shows deficiency, strength training several days a week, aerobic training aimed at building cardiorespiratory fitness, and consistent, adequate sleep. These interventions are achievable for roughly $100 to $400 per month in direct costs, and most have some form of controlled human trial evidence behind at least part of their rationale.

The Medium-Value Additions (Reasonable Bets With Physician Oversight)

If budget allows and a physician is supervising, adding rapamycin pulse dosing, acarbose with carbohydrate-heavy meals, NMN or NR supplementation, and a CGM for a defined period of metabolic feedback adds mechanistic coverage without strong outcome trial support yet. This layer adds roughly $200 to $600 per month and carries more uncertainty and, in the case of rapamycin, more monitoring burden.

The High-Cost, Low-Evidence Layer

Frequent full-body MRI, most peptide injections without a specific diagnosed indication, and proprietary longevity supplements sold with limited independent trial data represent the lowest evidence-to-cost interventions in the stack. A person without symptoms or a strong family history is making a very different risk-benefit decision than someone with a known hereditary cancer risk, and that decision needs individualized physician input rather than a general recommendation either way.

What Physicians Are Saying About the Blueprint Protocol

The longevity medicine field has responded to Blueprint with a mix of clinical interest and measured skepticism. Peter Attia, M.D., a physician specializing in longevity medicine, has publicly commented that Johnson's project is genuinely interesting as a data-collection exercise, but that the causal inference problem in an n-of-1 experiment is essentially unsolvable: it is not possible to know with confidence which of dozens of simultaneous interventions is responsible for any single observed change. This is a paraphrase of publicly discussed commentary rather than a verified verbatim quotation, and readers who want the exact wording should check Attia's own published or recorded statements directly.

The American College of Lifestyle Medicine's position statement on chronic disease and healthy aging describes therapeutic nutrition, physical activity, restorative sleep, and stress resilience as the foundation of healthy aging. [15] That view aligns with the non-drug components of Blueprint while stopping well short of endorsing the full prescription drug stack, which remains outside the scope of a lifestyle medicine position statement.

Population-Specific Evidence and Transferability Map

The interventions in Johnson's stack were studied in specific populations, doses, and settings. Applying them to a generally healthy adult who does not match that studied population is an extrapolation, even when the underlying drug or supplement is well established for its approved use. This table separates what is directly studied from what is extrapolated, flags where specialist input matters most, and lists what a physician would actually want to track.

The pattern across nearly every row is the same: the strongest evidence sits in a specific patient population with a specific risk profile, and moving that evidence to a healthy adult without those risk factors is a judgment call that belongs to a physician, not a default assumption.

Real-World Cost Summary

The midpoint of the non-celebrity range is roughly $2,000 per month, or $24,000 per year. Johnson has not published a category-by-category breakdown of his own $2 million figure, so this table compares his one disclosed total against a bottom-up, non-celebrity estimate rather than a like-for-like accounting.